Although MGMT methylation status is not used in the integrated diagnosis of glioblastoma, it remains a critical prognostic tool as there are significant variations in clinical response to standard-of-care treatments (temozolomide) based on the status of MGMT. The gene discussed is MGMT; the disease is glioblastoma.